Tims China Surpasses 20 Million Loyalty Club Members
SHANGHAI, China and NEW YORK, April 09, 2024 (GLOBE NEWSWIRE) — TH International Limited (“Tims China” (Nasdaq: THCH)), the exclusive […]
NOVONIX Announces Participation in April Investor Events
BRISBANE, Australia, April 10, 2024 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX”), a leading battery materials and […]
Mobile-health Network Solutions Announces Pricing of $9 Million Initial Public Offering
Singapore, April 09, 2024 (GLOBE NEWSWIRE) — Mobile-health Network Solutions (“MNDR” or the “Company”), a leading telehealth solutions provider in […]
Exponent to Announce First Quarter of Fiscal Year 2024 Results and Host Quarterly Conference Call on April 25, 2024
MENLO PARK, Calif., April 09, 2024 (GLOBE NEWSWIRE) — Exponent, Inc. (Nasdaq: EXPO), today announced that it will report First […]
NorthWestern to Host First Quarter 2024 Financial Results Webinar and Notice of Virtual Annual Stockholders Meeting
BUTTE, Mont. and SIOUX FALLS, S.D., April 09, 2024 (GLOBE NEWSWIRE) — NorthWestern Energy Group, Inc. d/b/a NorthWestern Energy (Nasdaq: […]
Great Elm Capital Corp. Prices Public Offering of $30,000,000 of 8.50% Notes Due 2029
PALM BEACH GARDENS, Fla., April 09, 2024 (GLOBE NEWSWIRE) — Great Elm Capital Corp. (the “Company” or “GECC”) (NASDAQ: GECC) […]
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
– Twenty patients with indolent (n=18) and aggressive (n=2) R/R B-NHL received evorpacept plus standard rituximab and lenalidomide (“R2”)– Evorpacept plus […]
Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024
Poster outlines the parameters for developing a flow-cytometry-based PPMP as a companion diagnostic to predict volasertib responders, based on a […]
APA Corporation Announces Updates to Executive Leadership
HOUSTON, April 09, 2024 (GLOBE NEWSWIRE) — APA Corporation (Nasdaq: APA) has announced updates to its executive leadership team to […]
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at […]
